You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Rapastinel


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Rapastinel?

Rapastinel is an investigational drug.

There have been 15 clinical trials for Rapastinel. The most recent clinical trial was a Phase 3 trial, which was initiated on October 15th 2016.

The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Naurex, Inc, an affiliate of Allergan plc, Allergan, and Naurex, Inc.

There are twenty-five US patents protecting this investigational drug and two hundred and twenty-seven international patents.

Recent Clinical Trials for Rapastinel
TitleSponsorPhase
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)Naurex, Inc, an affiliate of Allergan plcPhase 3
Assessment of Effect of Rapastinel on Driving PerformanceNaurex, Inc, an affiliate of Allergan plcPhase 1
Assessment of Abuse Potential of Rapastinel in HumansNaurex, Inc, an affiliate of Allergan plcPhase 1

See all Rapastinel clinical trials

Clinical Trial Summary for Rapastinel

Top disease conditions for Rapastinel
trials012345678910111213Depressive Disorder, MajorDepressive DisorderDepressionDisease[disabled in preview]
Top clinical trial sponsors for Rapastinel
trials02468101214Naurex, Inc, an affiliate of Allergan plcAllerganNaurex, Inc[disabled in preview]

See all Rapastinel clinical trials

US Patents for Rapastinel

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Rapastinel ⤷  Subscribe Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx Inc. (Evanston, IL) ⤷  Subscribe
Rapastinel ⤷  Subscribe Spiro-lactam NMDA modulators and methods of using same Aptinyx Inc. (Evanston, IL) ⤷  Subscribe
Rapastinel ⤷  Subscribe Class of mu-opioid receptor agonists THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY) ⤷  Subscribe
Rapastinel ⤷  Subscribe Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx Inc. (Evanston, IL) ⤷  Subscribe
Rapastinel ⤷  Subscribe Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx Inc. (Evanston, IL) ⤷  Subscribe
Rapastinel ⤷  Subscribe Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx Inc. (Evanston, IL) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 6 of 6 entries

International Patents for Rapastinel

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Rapastinel Australia AU2014212484 2033-01-29 ⤷  Subscribe
Rapastinel Brazil BR112015018087 2033-01-29 ⤷  Subscribe
Rapastinel Canada CA2898861 2033-01-29 ⤷  Subscribe
Rapastinel Chile CL2015002121 2033-01-29 ⤷  Subscribe
Rapastinel Chile CL2015002125 2033-01-29 ⤷  Subscribe
Rapastinel China CN105229011 2033-01-29 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 6 of 6 entries

Rapastinel: A Promising yet Challenged Depression Drug Candidate

Introduction to Rapastinel

Rapastinel, formerly known as GLYX-13, is an investigational drug developed by Allergan (now part of AbbVie) for the treatment of Major Depressive Disorder (MDD). This drug candidate has garnered significant attention due to its unique mechanism of action and rapid antidepressant effects, similar to those of ketamine but without the psychotomimetic side effects.

Mechanism of Action

Rapastinel is characterized as a modest and selective positive NMDA receptor modulator. Unlike ketamine, it enhances NMDAR activity through a novel site independent of the glycine co-agonist site. This unique mechanism allows rapastinel to induce rapid and sustained antidepressant effects along with increased synaptic plasticity, as observed in preclinical and Phase 2 clinical studies[2][3].

Clinical Trials and Development

Phase 2 Successes

In Phase 2 clinical trials, rapastinel demonstrated a rapid onset of antidepressant effect within one day, which continued for approximately seven days after a single injection. These results were promising, especially for patients who had an inadequate response to one or more antidepressants[3].

Phase 3 Challenges

However, the Phase 3 clinical trials did not yield the expected outcomes. In three acute studies (RAP-MD-01, -02, -03), rapastinel did not differentiate from placebo on the primary and key secondary endpoints. An interim analysis of the relapse prevention study (RAP-MD-04) also suggested that the primary and key secondary endpoints would not be met[2].

Formulation and Administration

Injectable Formulation

Initially, rapastinel was developed as an intravenous formulation. Despite its efficacy, the injectable form posed a significant barrier to widespread adoption due to patient aversion to injections[1].

Oral Pill Formulation

To address this issue, Allergan announced plans to develop an oral pill formulation of rapastinel. This oral version aims to mimic or complement the effects of the injectable form, potentially making the treatment more accessible and widely used[1].

Market Projections and Competition

Market Growth

The US market for major depressive disorders (MDD) is projected to grow significantly, reaching $4.6 billion by 2025. This growth is driven by the increasing demand for effective treatments and the introduction of new drugs in the late-stage pipeline[5].

Competitive Landscape

Rapastinel is part of a competitive landscape that includes other promising drugs such as Janssen’s esketamine, Axsome Therapeutics’ AXS-05, and Alkermes’ ALKS-5461. Despite the challenges faced by rapastinel, it is still considered a potential player in this market. GlobalData estimates that these pipeline drugs, including rapastinel, will generate over $800 million by 2025[5].

Future Outlook

Ongoing Research and Development

Despite the setbacks in Phase 3 trials, Allergan and other pharmaceutical companies remain committed to advancing new treatment options for MDD. The development of an oral pill formulation of rapastinel and other related compounds, such as NRX-1074, an orally available derivative of rapastinel, continues to be a focus area[3][4].

Regulatory Pathway

The company plans to file for FDA approval within the next few years, although the exact timeline may be influenced by the outcomes of ongoing and future clinical trials. The regulatory pathway remains crucial for the eventual market entry of rapastinel[1].

Expert Insights

"As soon as there’s a breakthrough, all those other companies that dropped out will want back in," said David Nicholson, Executive Vice President and President of Global R&D brands at Allergan. This sentiment reflects the high interest and potential impact of breakthrough treatments like rapastinel in the depression treatment market[1].

Key Takeaways

  • Rapid Antidepressant Effects: Rapastinel has shown rapid onset of antidepressant effects in clinical trials.
  • Unique Mechanism: It works as a selective positive NMDA receptor modulator, distinct from ketamine.
  • Phase 3 Challenges: The drug did not meet primary endpoints in Phase 3 trials.
  • Oral Formulation: Development of an oral pill formulation is underway to enhance patient compliance.
  • Market Potential: Despite challenges, rapastinel is projected to contribute to the growing MDD treatment market.
  • Regulatory Pathway: FDA approval is anticipated but depends on future clinical trial outcomes.

FAQs

Q: What is rapastinel, and how does it differ from ketamine?

A: Rapastinel is an investigational drug for MDD that works as a selective positive NMDA receptor modulator, similar to ketamine but without the psychotomimetic side effects.

Q: What were the outcomes of the Phase 3 clinical trials for rapastinel?

A: The Phase 3 trials did not meet the primary and key secondary endpoints, indicating that rapastinel did not differentiate from placebo.

Q: Why is an oral pill formulation of rapastinel being developed?

A: The oral formulation aims to address patient aversion to injections and make the treatment more accessible and widely used.

Q: What is the market projection for rapastinel and other new MDD treatments?

A: The US MDD market is projected to reach $4.6 billion by 2025, with new pipeline drugs, including rapastinel, expected to generate over $800 million.

Q: What other compounds are related to rapastinel and in development?

A: NRX-1074, an orally available derivative of rapastinel, is also in development as a monotherapy treatment for MDD.

Sources

  1. Lori Calabrese MD Blog: "A 'breakthrough' depression drug inspired by ketamine is attracting more attention from big pharma."
  2. BioSpace: "Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)."
  3. PR Newswire: "Rapastinel (GLYX-13) Shown to Improve Ketamine or PCP-Induced Cognitive Impairment in Mice."
  4. Drug Discovery Trends: "Gate Neurosciences taps event-driven pharmacology in depression."
  5. Pharmaceutical Executive: "Depression Drugs Sales in the US to Reach $4.6 billion by 2025."

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.